Risultati per: Percorsi personalizzati contro il cancro legati al gene BRCA

New England Journal of Medicine, Ahead of Print.

This case report describes a man in his 40s who presented with a 5-month history of recurrent pruritic papular erythema with mild scaling on the face, left forearm, and groin.

This retrospective analysis of data from 3 randomized clinical trials examines the association of pathologic complete response with event-free survival by intrinsic subtype and other gene expression signatures in patients with ERBB2/HER2-positive early breast cancer treated in the neoadjuvant setting

Studio su topi, migliore risposta immunitaria

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

Oncologi, ‘non c’è possibilità di diagnosi precoce. Primi risultati positivi per la targeted therapy’

La mutazione aumenta l’abilità del cervello di ripulirsi

Indispensabile intervenire per correggere gli stili di vita e intercettare i fattori prodromici che favoriscono la cancerogenesi

In Reply We thank Dr Narod for his comment on our recent research article evaluating the safety of pregnancy following breast cancer in young women with germline BRCA pathogenic or likely pathogenic variants. In his Letter, Narod noted that our primary analysis did not control for the potentially protective effect of risk-reducing bilateral salpingo-oophorectomy in this patient cohort.

To the Editor In the article by Dr Lambertini and colleagues on pregnancy after breast cancer in young BRCA carriers, the authors compared the outcomes of patients with breast cancer and BRCA1 or BRCA2 variants according to whether or not they had a pregnancy after having breast cancer. They found no effect of pregnancy on the outcome of disease-free survival (local recurrence, contralateral breast cancer, distant recurrence) (hazard ratio, 0.99; 95% CI, 0.81-1.20) but found a significant improvement in breast cancer–specific survival (death due to breast cancer) with pregnancy (hazard ratio, 0.53; 95% CI, 0.37-0.74; P 

Recently, Lopes et al quantified the effect of modifiable lifestyle factors in inflammatory bowel disease (IBD) prevention using population attributable risk, and reported that 42.9% of Crohn’s disease (CD) cases and 44.4% of ulcerative colitis (UC) cases could have been prevented by lifestyle interventions. This interesting result was based on 6 prospective cohorts including 3 US cohorts with 208 070 participants and 3 large European cohorts that were used for validation.1 Undoubtedly, this well-performed study illustrates the possible merits of lifestyle modification as a prevention strategy for IBD. However, we would like to argue that lifestyle modification as such cannot be uncoupled from the genetic background. Although the importance of genetic susceptibility in the development of IBD is widely accepted,2 this was unfortunately not assessed in Lopes et al ‘s study. We recently conducted a prospective cohort study on the UK Biobank in >450 000 individuals,…